884,151 results match your criteria cancer therapy


Phase 2 multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-vs-host disease.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States.

Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal and transient responses in a significant number of patients. Safety and feasibility of anti-CD20 directed B-cell therapy with ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day) was previously established in our phase I trial (n=12). Read More

View Article and Full-Text PDF
October 2021

Multiple Myeloma Cells Depend on the DDI2/NRF1-mediated Proteasome Stress Response for Survival.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

Harvard Medical School, United States.

Multiple myeloma (MM) cells suffer from baseline proteotoxicity due to an imbalance between the load of misfolded proteins awaiting proteolysis and the capacity of the ubiquitin-proteasome system to degrade them. This intrinsic vulnerability is at the base of MM sensitivity to agents that perturb proteostasis such as proteasome inhibitors (PIs), the mainstay of modern-day myeloma therapy. De-novo and acquired PI resistance are important clinical limitations, adversely affecting prognosis. Read More

View Article and Full-Text PDF
October 2021

INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

Incyte Corporation, Wilmington, Delaware, United States.

Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested the efficacy and safety of ponatinib plus prednisone in newly diagnosed patients with Ph+ ALL aged ≥60 years, or unfit for intensive chemotherapy and stem cell transplantation. Read More

View Article and Full-Text PDF
October 2021

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

Group of Applied Clinical Research in Hematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute) Barcelona, Spain.

Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphomas (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 FL patients for HBV infection status, clinical features and gene mutational profile. Anti-HBc was detectable in sixteen patients (13. Read More

View Article and Full-Text PDF
October 2021

The Incidence of Cancer Associated Thrombosis is Increasing Over Time.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

University of California-Davis Cancer Center, Sacramento, California, United States.

Cancer associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage and therapy. We aimed to characterize the incidence, risk factors, temporal trends and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed 2005 -2017 and determine the 6 and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type and stage after adjusting for competing risk of death. Read More

View Article and Full-Text PDF
October 2021

Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.

Blood Adv 2021 Oct 14. Epub 2021 Oct 14.

Fred Hutchinson Cancer Research Center, United States.

Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCL), though outcomes are worse in aggressive disease and most patients will still experience relapse. Radioimmunotherapy (RIT) using 90Y-Ibritumomab tiuxetan can induce disease control across lymphoma subtypes in a dose-dependent fashion. We hypothesized that mega-doses of 90Y-Ibritumomab tiuxetan with reduced-intensity conditioning (RIC) could safely produce deeper remissions in aggressive BCL further maintained with the immunologic effect of allo-HCT. Read More

View Article and Full-Text PDF
October 2021

Emerging targets for anticancer vaccination: PD-1.

ESMO Open 2021 Oct 11;6(5):100278. Epub 2021 Oct 11.

Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address:

Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Inhibition of the PD-1/PD-L1 pathway with monoclonal antibodies as immune checkpoint inhibitors targeting PD-1 or its ligand, PD-L1, represents a milestone in cancer therapy. The application of these antibodies, however, suffers from drawbacks including failure to show a response or benefit in a majority of patients following monotherapy or combination therapy, their frequent administration, and cost intensiveness. Read More

View Article and Full-Text PDF
October 2021

Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling.

Phytomedicine 2021 Sep 27;93:153781. Epub 2021 Sep 27.

Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan, China; Key Laboratory of Effective Substances Research and Utilization in TCM of Shanxi Province, Taiyuan, China. Electronic address:

Background: Hepatocellular carcinoma (HCC) is one of the most extensive and most deadly cancers worldwide. The invasion and metastasis characteristics of HCC dramatically affect the prognosis and survival of HCC patients. Compound Kushen Injection (CKI) is a GMP produced, proverbially applied traditional Chinese medicine formula in China to treat cancer-associated pains, and used as an adjunctive therapy for HCC. Read More

View Article and Full-Text PDF
September 2021

HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway.

Bioorg Chem 2021 Oct 4;117:105396. Epub 2021 Oct 4.

Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, the Netherlands. Electronic address:

Non-small-cell lung carcinoma (NSCLC) is one of the most common forms of lung cancer, and a leading cause of cancer death among human beings. There is an urgent demand for novel therapeutics for the treatment of NSCLC to enhance the efficacy of the currently applied Tyrosine kinase inhibitors (TKIs) therapy and to overcome therapy-resistance. Here, we report a novel small-molecule inhibitor that simultaneously targets histone deacetylase (HDAC) and macrophage migration inhibitory factor (MIF). Read More

View Article and Full-Text PDF
October 2021

68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study.

Transl Oncol 2021 Oct 11;15(1):101242. Epub 2021 Oct 11.

Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, 525 E 68th Street, New York, NY 10065, USA.

Background: The primary objective was to compare the overall diagnostic performance, presented as detection rate of Ga-PSMA-HBED-CC positron emission tomography/magnetic resonance imaging (PSMA PET/MRI) versus conventional, multiparametric MRI (mpMRI) in a population of patients with biochemically recurrent prostate cancer. In conjunction with this analysis, secondary objectives included the evaluation of the detection rate stratified by PSA levels and primary treatment modality.

Methods: A total of 165 PSMA PET MRI were performed from April 2018 to May 2021, of whom 108 were presenting for biochemical recurrent disease. Read More

View Article and Full-Text PDF
October 2021

The Role of Long Term Label-Retaining Cells in the Treatment of Erectile Dysfunction by Vacuum Erectile Device.

Sex Med 2021 Oct 11;9(6):100442. Epub 2021 Oct 11.

Department of Surgery, The University of Texas Health Science Center at Houston, Houston, TX, USA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Introduction: Vacuum erectile device (VED) therapy is commonly used for penile rehabilitation after radical prostatectomy, however, the underlying mechanism of this effect is not fully understood.

Aim: To evaluate the presence of label-retaining cells (LRCs), cells with long-term retention of 5-ethynyl-2-deoxyuridine (EdU) labeling and recognized as adult stem cells or progenitor-like cells, in cavernous tissue after VED treatment using a BCNC rat model.

Methods: Postnatal pups (1 day old) of Sprague Dawley (SD) rats were intraperitoneally injected with EdU (50 ug/g, BID for 3 days) and BCNC surgery was conducted at 6 weeks old (designated as natal-labeled rats). Read More

View Article and Full-Text PDF
October 2021

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

Lung Cancer 2021 Sep 21;162:9-15. Epub 2021 Sep 21.

Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. Electronic address:

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be defined. Overall survival (OS) is influenced by the availability/use of subsequent therapy after first-line treatment. Read More

View Article and Full-Text PDF
September 2021

Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma.

Int Immunopharmacol 2021 Oct 11;101(Pt A):108183. Epub 2021 Oct 11.

Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China. Electronic address:

Glioma is the most commonly diagnosed primary tumor of central nervous system. Previous studies found that the six-transmembrane epithelial antigen of prostate (STEAP) family can regulate the biological behaviors of several cancers. However, the role of STEAP family in glioma remains unclear. Read More

View Article and Full-Text PDF
October 2021

Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.

Eur J Med Chem 2021 Oct 5;227:113897. Epub 2021 Oct 5.

The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510720, China; Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China. Electronic address:

Microtubule target agents (MTAs) are widely-used clinical anti-cancer drugs for decades, but the acquired drug resistance severely restricted their application. Thioredoxin reductases (TrxR) was reported to be overexpressed in most tumors and closely related to high risk of cancer recurrence and drug resistance, making it a potential target for anticancer drug discovery. Multi-target-directed ligands (MTDLs) by a single molecule provide a logical and alternative approach to drug combinations. Read More

View Article and Full-Text PDF
October 2021

HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION.

Transplant Cell Ther 2021 Oct 11. Epub 2021 Oct 11.

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

Background: There are limited data on outcomes of patients with prior Coronavirus disease 2019 (COVID-19) who proceeded to autologous or allogeneic hematopoietic cell transplantation (HCT). It is unknown whether these patients are more susceptible to poor outcomes and recurrence of COVID-19.

Objective: We report a retrospective analysis of outcomes of 15 consecutive patients with hematologic malignancies who experienced COVID-19 and subsequently underwent autologous (n=8) or allogeneic (n=7) HCT between 6/17/20 and 2/17/21. Read More

View Article and Full-Text PDF
October 2021

Chitosan-tripolyphosphate nanoparticles-mediated co-delivery of MTHFD1L shRNA and 5-aminolevulinic acid for combination photodynamic-gene therapy in oral cancer.

Photodiagnosis Photodyn Ther 2021 Oct 11:102581. Epub 2021 Oct 11.

Department of Stomatology, PLA Strategic Support Force Medical Center, Beijing, 100101, China;; PLA 306 Clinical College of Anhui Medical University, Hefei, 230001, China.. Electronic address:

Background: Rationally designed nanostructured materials can produce ideal drug carriers that plays an increasingly important role in cancer treatment. In comparison with conventional drug combination approaches, using co-delivery systems of multiple drugs achieves sophisticated targeting strategies and multifunctionality.

Methods: First, a nano-co-delivery of chitosan/tripolyphosphate (CS-TPP) was synthesized and characterized combining 5-aminolevulinic acid photodynamic therapy (ALA-PDT) with methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) shRNA. Read More

View Article and Full-Text PDF
October 2021

RNA methylation and cancer treatment.

Pharmacol Res 2021 Oct 11:105937. Epub 2021 Oct 11.

Department of Clinical Medical Research Center, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, PR China; Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, PR China; School of Life and Health Sciences, The Chinese University of Kong Hong, Shenzhen, China. Electronic address:

To this date, over 100 different types of RNA modification have been identified. Methylation of different RNA species has emerged as a critical regulator of transcript expression. RNA methylation and its related downstream signaling pathways are involved in plethora biological processes, including cell differentiation, sex determination and stress response, and others. Read More

View Article and Full-Text PDF
October 2021

Lung cancer driven by BRAF mutation is targetable by EGFR kinase inhibitors.

J Thorac Oncol 2021 Oct 11. Epub 2021 Oct 11.

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Introduction: Mutations in BRAF occur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not currently available for patients harboring non-V600 BRAF mutations. Read More

View Article and Full-Text PDF
October 2021

Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.

Gene 2021 Oct 11:145992. Epub 2021 Oct 11.

Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo Yinzhou No 2. Hospital, Ningbo, China. Electronic address:

Renal cell carcinoma (RCC) is a common type of urological cancer and is often diagnosed at an advanced stage. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is used as second-line therapy for sorafenib- or sunitinib-refractory metastatic RCC. However, the clinical benefits of Everolimus are often hampered by drug resistance. Read More

View Article and Full-Text PDF
October 2021

Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.

Gene 2021 Oct 11:146003. Epub 2021 Oct 11.

Department of Obstetrics and Gynecology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, China.

Objective: Chronotherapy, a promising therapy, may build up the chemotherapy efficacy through thinking about timing of therapy. Here, we observed the roles of period circadian regulator 2 (PER2) on cervical cancer progression and the therapeutic efficacy of cisplatin (DDP) based on the circadian rhythm of PER2.

Methods: When Hela/DDP and SiHa/DDP transfected with pcDNA3. Read More

View Article and Full-Text PDF
October 2021

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

J Hepatol 2021 Oct 11. Epub 2021 Oct 11.

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria; Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Background: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). Prognostic biomarkers are an unmet need.

Methods: Patients with HCC put on PD-(L)1-based immunotherapy in 6 European centers (training set; n=190) and in 8 European centers (validation set; n=102) were included. Read More

View Article and Full-Text PDF
October 2021

Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications.

J Control Release 2021 Oct 11. Epub 2021 Oct 11.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030, United States of America. Electronic address:

Non-surgical treatment options for low-grade endometrial cancer and precancerous lesions are a critical unmet need for women who wish to preserve fertility or are unable to undergo hysterectomy. The PI3K/AKT/mTOR pathway is frequently activated in endometrial cancers and has been associated with resistance to endocrine therapy, making it a compelling target for early stage disease. Oral everolimus, an inhibitor against mTORC1, has shown clinical benefit in advanced or recurrent disease but has severe adverse effects that may lead to treatment interruption or dose reduction. Read More

View Article and Full-Text PDF
October 2021

Determination of in vivo virtue of dermal targeted combinatorial lipid nanocolloidal based formulation of 5-fluorouracil and resveratrol against skin cancer.

Int J Pharm 2021 Oct 11:121179. Epub 2021 Oct 11.

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, INDIA. Electronic address:

The current study has been designed to appraise the efficacy of developed combinatorial lipid-nanosystem-based gel (linogel) of 5-fluorouracil and resveratrol for skin cancer treatment. Initially, linogel was prepared and characterized for different parameters, namely pH, texture, drug content uniformity, occlusiveness, etc. Then in vivo efficacy studies (tumor number, area, and volume, histopathology, ultrastructural and immunohistochemical analysis) of linogel were determined over-developed skin tumors. Read More

View Article and Full-Text PDF
October 2021

Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: differences between tangential beam and VMAT.

Radiother Oncol 2021 Oct 11. Epub 2021 Oct 11.

Department of Radiation Oncology, Breast Working Group, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium. Electronic address:

BACKGROUNDAND PURPOSE: to evaluate dosimetric differences in unintended dose to the lower axilla between 3D-standard (3DCRT), tangential beam forward intensity modulated radiotherapy (F-IMRT) and volumetric modulated arc therapy (VMAT). The objective is to evaluate whether results of clinical trials, such as the ACOSOG-Z011 trial, that evaluated omission of axillary clearance can be extrapolated towards more conformal techniques like VMAT.

Materials And Methods: twenty-five consecutive patients treated with whole breast radiotherapy alone (WBRT) using a F-IMRT technique were identified. Read More

View Article and Full-Text PDF
October 2021

STEREOTACTIC BODY RADIOTHERAPY FOR HEAD AND NECK SKIN CANCER.

Radiother Oncol 2021 Oct 11. Epub 2021 Oct 11.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address:

Aim: To report outcomes of Stereotactic Body Radiotherapy (SBRT) for head and neck skin cancer (HNSC) patients treated at a high-volume centre.

Materials: A retrospective review of HNSC SBRT patients from 2012-2019 was conducted. Kaplan-Meier method was used to estimate local control (LC), locoregional control (LRC) outside of SBRT field, overall survival (OS), progression-free survival (PFS) and late toxicity (LT). Read More

View Article and Full-Text PDF
October 2021

Decellularized ECM derived from normal bone involved in the viability and chemo-sensitivity in Multiple myeloma cells.

Exp Cell Res 2021 Oct 11:112870. Epub 2021 Oct 11.

Research Center of Clinical Medical, Affiliated Hospital of Nantong University, Nantong, Jiangsu province 226001, P. R. China. Electronic address:

Multiple myeloma (MM) is an incurable plasma cell malignancy. The progression of MM is closely related to the bone microenvironment. Bone matrix proteins are remodeled and manipulated to govern cancer growth during the process of MM. Read More

View Article and Full-Text PDF
October 2021

Clinicopathological Features and Survival of Adolescent and Young Adults with Cervical Cancer.

Cancer Control 2021 Jan-Dec;28:10732748211051558

Center for Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, 26453The Second Affiliated Hospital of Wenzhou Medical University, People's Republic of China, Wenzhou, China.

Purpose: To explore clinicopathological characteristics and their prognostic value among young patients with cervical cancer (who are aged ≤25 years old).

Methods: The Surveillance, Epidemiology, and End Results Program (SEER) database was used to extract data on cervical cancer patients. They were then stratified by age as young women (≤25 years old) and old women (26-35 years old) and analyzed for clinicopathology characteristics and treatment modalities. Read More

View Article and Full-Text PDF
October 2021

Gene capsules as functional pharmaceutical formulations for delivery of DNA as an active substance.

Adv Clin Exp Med 2021 Oct 14. Epub 2021 Oct 14.

Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Warsaw, Poland.

Background: Capsules are solid drug forms that are well accepted by patients. Capsules usually consist of a medicinal substance with therapeutic benefits plus excipients. From a pharmaceutical point of view, DNA coding sequences can be treated as active substances. Read More

View Article and Full-Text PDF
October 2021

Immunity in acute myeloid leukemia: where the immune response and targeted therapy meet.

Eur J Immunol 2021 Oct 14. Epub 2021 Oct 14.

The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.

Acute myeloid leukemia (AML) is a highly aggressive disease with high relapse and mortality rates. Recent years have shown a surge in novel therapeutic development for AML, both in clinical and preclinical stages. These developments include targeted therapies based on AML specific molecular signatures as well as more general immune modulation and vaccination studies. Read More

View Article and Full-Text PDF
October 2021

Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV-negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy.

Int J Cancer 2021 Oct 14. Epub 2021 Oct 14.

Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Biomarkers with relevance for loco-regional therapy are needed in Human Papillomavirus negative aka HPV(-) Head and Neck Squamous Cell Carcinoma (HNSCC). Based on the premise that DNA methylation pattern is highly conserved, we sought to develop a reliable and robust methylome-based classifier identifying HPV(-) HNSCC patients at risk for loco-regional recurrence (LR) and all-event progression after postoperative radiochemotherapy (PORT-C). The training cohort consisted of HPVDNA negative HNSCC patients (n=128) homogeneously treated with PORT-C in frame of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. Read More

View Article and Full-Text PDF
October 2021